Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 46-53, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-928779
ABSTRACT
Lung cancer is one of the most prevalent malignancies with the highest morbidity and mortality rates worldwide. In recent years, with the development of immune-oncology research and several therapeutic antibodies have reach the clinic, many breakthroughs have been made in immunotherapy. The advent of immunotherapy has revolutionized the treatment of NSCLC, but the response and durable clinical benefit are only observed in a small subset of patients. Therefore, strategies to screen the potential beneficial population and improve the efficacy of immunotherapy remain an essential topic. In the current article, the author review the biomarkers that have potential to better predict responders to immunotherapy and to provide ideas for the clinical application of immunotherapy.
.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Biomarcadores de Tumor
/
Carcinoma de Pulmón de Células no Pequeñas
/
Antígeno B7-H1
/
Inmunoterapia
/
Neoplasias Pulmonares
Límite:
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Lung Cancer
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS